Syndax Pharmaceuticals SNDX Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $130.89M-15.0% | $134.93M-12.4% | $116.81M-12.2% | $108.64M+3.1% | $153.99M+34.4% | ||
| $221.17M-38.3% | $259.14M-38.1% | $319.17M+24.4% | $346.6M+8.4% | $358.2M+12.0% | ||
| $102K-53.0% | $102K-53.0% | $217K0.0% | $217K0.0% | $217K0.0% | ||
| $38.12M+142% | $38M+400% | $25.4M— | $19.45M— | $15.72M— | ||
| $34.95M+649% | $32.75M+8,849% | $25M— | $17.7M— | $4.66M— | ||
| $16.1M+90.3% | $13.5M+58.0% | $9.52M+93.9% | $9.88M+135% | $8.46M+81.4% | ||
| $471.18M-14.1% | $528.08M-12.4% | $529.83M+27.7% | $531.68M+19.2% | $548.75M+20.9% | ||
| $177K— | $181K— | $128K— | $0-100% | $0-100% | ||
| $1.21M-32.7% | $1.34M-33.6% | $1.47M+94.6% | $1.63M+62.9% | $1.8M+44.9% | ||
| $472.67M-26.2% | $529.71M-26.9% | $551.79M+29.6% | $596.15M+25.0% | $640.71M+18.0% | ||
| $10.84M+7.9% | $16.58M+42.6% | $13.83M+182% | $17.35M+50.0% | $10.05M+14.1% | ||
| $74.84M+33.7% | $103.06M+71.5% | $77.11M+60.2% | $71.07M+165% | $55.98M+67.6% | ||
| $350M+4.2% | $350M+3.6% | $327.08M— | $330.57M— | $335.85M— | ||
| $487K+29.2% | $470K-0.2% | $329K-60.9% | $344K-64.9% | $377K-63.8% | ||
| $86.17M-8.9% | $120.12M+16.0% | $114.19M+92.3% | $112.99M+166% | $94.55M+86.1% | ||
| $344.87M+4.2% | $344.96M+3.5% | $322.18M+16,108,650% | $325.74M+237,665% | $331.1M+99,031% | ||
| $431.05M+1.3% | $465.08M+6.5% | $436.36M+635% | $438.73M+930% | $425.65M+732% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $9K0.0% | $9K0.0% | $9K0.0% | $9K0.0% | $9K+12.5% | ||
| $1.59B+4.6% | $1.57B+4.1% | $1.55B+4.0% | $1.53B+3.9% | $1.52B+3.6% | ||
| -$1.55B-18.6% | -$1.51B-23.4% | -$1.44B-27.6% | -$1.38B-32.1% | -$1.31B-34.0% | ||
| $11K-97.9% | $452K+177% | $525K+41.5% | $285K+135% | $527K+170% | ||
| $41.62M-80.6% | $64.63M-77.6% | $115.43M-68.5% | $157.42M-63.8% | $215.06M-56.3% | ||
| $472.67M-26.2% | $529.71M-26.9% | $551.79M+29.6% | $596.15M+25.0% | $640.71M+18.0% | ||
| $20.51M— | $23.75M— | $15.74M— | $12.32M— | —— | ||
| $9.18M+123% | $19.62M+95.6% | $18.2M+8.4% | $13.47M+87.9% | $4.12M-52.0% | ||
| $267K-92.6% | $6.4M+76.2% | $0— | $3.63M+3.7% | $3.59M— | ||
| $1.21M-32.7% | $1.34M-33.6% | $1.47M+94.6% | $1.63M+62.9% | $1.8M+44.9% | ||
| $1.21M-32.7% | $1.34M-33.6% | $1.47M+94.6% | $1.63M+62.9% | $1.8M+44.9% | ||
| $221.17M-38.3% | $259.14M-38.1% | $319.17M+24.4% | $346.6M+8.4% | $358.2M+12.0% | ||
| $1.21M-32.7% | $1.34M-33.6% | $1.47M+94.6% | $1.63M+62.9% | $1.8M+44.9% | ||
| $1K-85.7% | $2K-77.8% | $2K-80.0% | $6K-50.0% | $7K-41.7% | ||
| —— | $0-100% | —— | —— | —— | ||
| $74.84M+33.7% | $103.06M+71.5% | $77.11M+60.2% | $71.07M+165% | $55.98M+67.6% | ||
| $350.49M+4.2% | $351.52M-47.6% | $327.4M+38,784% | $330.91M+29,605% | $336.23M+24,460% | ||
| $11K-97.9% | $452K+177% | $525K+41.5% | $285K+135% | $527K+170% | ||
| $1.59B+4.6% | $1.57B+4.1% | $1.55B+4.0% | $1.53B+3.9% | $1.52B+3.6% | ||
| $9K0.0% | $9K0.0% | $9K0.0% | $9K0.0% | $9K+12.5% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $907K-37.6% | $1.05M-33.4% | $1.19M+59,400% | $1.33M+33,025% | $1.45M+20,657% | ||
| $267K-92.6% | $6.4M+76.2% | $0— | $3.63M+3.7% | $3.59M— | ||
| —— | $343.91M+3.7% | —— | —— | —— | ||
| $343.97M+4.3% | $343.91M+3.7% | $320.99M— | $324.41M— | $329.64M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Syndax Pharmaceuticals cover its short-term obligations?
- Its current ratio is 5.47 — current assets exceed current liabilities.
- Where does Syndax Pharmaceuticals's balance sheet data come from?
- Every line is extracted from Syndax Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.